论文部分内容阅读
目的 探讨减轻阿托品试验药物对老年人不良影响的方法。方法 1 2 5例老年人以分法注射进行阿托品试验 ,其中 44例前列腺增生者适当禁饮。结果 前列腺增生者虽仍多有程度不同的尿潴留 ,但均能耐受 ,无一导尿 ,且禁饮对肾小球滤过功能、血电解质及尿酸均无明显影响。 1 2 5例中 2 9例出现房速 ,最高心室率 1 1 6次 /分 ,无 1例出现严重心律失常或心绞痛。均有不同程度的头昏、口干。不良反应程度与剂量相关。结论 阿托品试验对于老年人仍较安全 ,分法注射则可在不影响结果的前提下减少阿托品的用量 ,从而减轻不良反应。
Objective To explore ways to reduce the adverse effects of atropine test drugs on the elderly. Methods A total of 125 elderly people were injected subcutaneously with atropine test, of which 44 cases of benign prostatic hyperplasia were forbidden to drink. Results Although hyperplasia of prostatic hyperplasia still had different degrees of urinary retention, all of them were tolerant and had no catheterization. And forbidden drink had no significant effect on glomerular filtration function, blood electrolytes and uric acid. Among 125 cases, 29 cases had atrial tachycardia and the highest ventricular rate was 116 times a minute. None of the patients had severe arrhythmia or angina pectoris. Have different degrees of dizziness, dry mouth. Adverse reactions and dose-related. Conclusions Atropine test is still safe for the elderly. Sub-injection can reduce the amount of atropine without affecting the result, thus reducing the adverse reaction.